Astatine-211 based radionuclide therapy: Current clinical trial landscape

Astatine-211 ((211)At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Albertsson, Per, Bäck, Tom, Bergmark, Karin, Hallqvist, Andreas, Johansson, Mia, Aneheim, Emma, Lindegren, Sture, Timperanza, Chiara, Smerud, Knut, Palm, Stig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859440/
https://www.ncbi.nlm.nih.gov/pubmed/36687417
http://dx.doi.org/10.3389/fmed.2022.1076210
_version_ 1784874355617955840
author Albertsson, Per
Bäck, Tom
Bergmark, Karin
Hallqvist, Andreas
Johansson, Mia
Aneheim, Emma
Lindegren, Sture
Timperanza, Chiara
Smerud, Knut
Palm, Stig
author_facet Albertsson, Per
Bäck, Tom
Bergmark, Karin
Hallqvist, Andreas
Johansson, Mia
Aneheim, Emma
Lindegren, Sture
Timperanza, Chiara
Smerud, Knut
Palm, Stig
author_sort Albertsson, Per
collection PubMed
description Astatine-211 ((211)At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
format Online
Article
Text
id pubmed-9859440
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98594402023-01-21 Astatine-211 based radionuclide therapy: Current clinical trial landscape Albertsson, Per Bäck, Tom Bergmark, Karin Hallqvist, Andreas Johansson, Mia Aneheim, Emma Lindegren, Sture Timperanza, Chiara Smerud, Knut Palm, Stig Front Med (Lausanne) Medicine Astatine-211 ((211)At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects. Frontiers Media S.A. 2023-01-06 /pmc/articles/PMC9859440/ /pubmed/36687417 http://dx.doi.org/10.3389/fmed.2022.1076210 Text en Copyright © 2023 Albertsson, Bäck, Bergmark, Hallqvist, Johansson, Aneheim, Lindegren, Timperanza, Smerud and Palm. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Albertsson, Per
Bäck, Tom
Bergmark, Karin
Hallqvist, Andreas
Johansson, Mia
Aneheim, Emma
Lindegren, Sture
Timperanza, Chiara
Smerud, Knut
Palm, Stig
Astatine-211 based radionuclide therapy: Current clinical trial landscape
title Astatine-211 based radionuclide therapy: Current clinical trial landscape
title_full Astatine-211 based radionuclide therapy: Current clinical trial landscape
title_fullStr Astatine-211 based radionuclide therapy: Current clinical trial landscape
title_full_unstemmed Astatine-211 based radionuclide therapy: Current clinical trial landscape
title_short Astatine-211 based radionuclide therapy: Current clinical trial landscape
title_sort astatine-211 based radionuclide therapy: current clinical trial landscape
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859440/
https://www.ncbi.nlm.nih.gov/pubmed/36687417
http://dx.doi.org/10.3389/fmed.2022.1076210
work_keys_str_mv AT albertssonper astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT backtom astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT bergmarkkarin astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT hallqvistandreas astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT johanssonmia astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT aneheimemma astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT lindegrensture astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT timperanzachiara astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT smerudknut astatine211basedradionuclidetherapycurrentclinicaltriallandscape
AT palmstig astatine211basedradionuclidetherapycurrentclinicaltriallandscape

Ejemplares similares